The results revealed that effective suppression of the CXCL12/CXCR4 axis and Notch pathway through AMD3100-assisted siRNA therapy is promising for the inhibition of macrophage migration to inflammatory sites, thereby preventing hepatic fibrosis and alleviating MASLD. Here, CXCL12 is linked to metabolic dysfunction-associated steatotic liver disease.